Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer

NCT04554927 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2020-09-03
Last updated
2026-05-18

Condition(s) studied

Web-applicationBreast CancerHormono Therapy

Investigational drug(s) / intervention(s)

WEB-ApplicationStandard accompaniment

WEB-Application: The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).

Standard accompaniment: Personalized schedule of medical follow-up given to the patient

Study summary

The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient \> 18 years old * Breast cancer patient candidate for adjuvant hormone therapy * Mastery of the French language * Patient with a cell phone and an Internet connection * Patient able to use a computer, smartphone, or tablet. * Patient affiliated to a social security system * Signing of informed consent prior to any specific study-related procedure Exclusion Criteria: * Patient who has previously received hormone therapy for cancer. * Patient not trained in the use of the application * Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study * Patients with locoregional or metastatic recurrence * Other history of cancer. * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool * Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons

Primary outcome measure(s)

  • Observance of hormontherapy — 18 months
    Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)

Trial sites (1)

FacilityCityRegionStatus
Centre François baclesse Caen France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04554927 on ClinicalTrials.gov ↗ ← All trials in France